We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

46 hedge funds and large institutions have $113M invested in MoonLake Immunotherapeutics in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

10% more funds holding

Funds holding: 42 → 46 (+4)

4.41% more ownership

Funds ownership: 89.42% → 93.83% (+4.4%)

3% more capital invested

Capital invested by funds: $109M → $113M (+$3.8M)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

Holders
46
Holders Change
+4
Holders Change %
+9.52%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
9
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
+$2.03M
2
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$711K
3
GCL
Glazer Capital LLC
New York
+$576K
4
PCM
Prelude Capital Management
New York
+$508K
5
Millennium Management
Millennium Management
New York
+$363K

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$1.52M
2
HM
HealthCor Management
New York
-$613K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$365K
4
SCM
Suvretta Capital Management
New York
-$361K
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$106K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
26
Glazer Capital LLC
New York
$599K +$576K +56,748 +5,154%
Millennium Management
27
Millennium Management
New York
$577K +$363K +35,735 +179%
LGM
28
Logos Global Management
California
$518K -$1.52M -150,000 -75%
PCM
29
Prelude Capital Management
New York
$518K +$508K +50,000 New
MS
30
Maven Securities
Jersey
$513K – – –
Janus Henderson Group
31
Janus Henderson Group
United Kingdom
$497K – – –
TD Asset Management
32
TD Asset Management
Ontario, Canada
$444K – – –
MWM
33
Meridian Wealth Management
Kentucky
$279K +$82.3K +8,100 +43%
RCM
34
Radcliffe Capital Management
Pennsylvania
$260K +$52.1K +5,131 +26%
EAM
35
Exos Asset Management
New York
$260K +$204K +20,100 +402%
ECM
36
ExodusPoint Capital Management
New York
$259K – – –
Nomura Holdings
37
Nomura Holdings
Japan
$255K -$518 -51 -0.2%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$238K +$234K +23,013 New
CC
39
Caxton Corporation
New Jersey
$165K – – –
HF
40
HRT Financial
New York
$147K – – –
PAM
41
Panagora Asset Management
Massachusetts
$74K -$416 -41 -0.6%
Morgan Stanley
42
Morgan Stanley
New York
$61K -$10 -1 -0%
UBS Group
43
UBS Group
Switzerland
$4K +$3.8K +374 New
SCM
44
Silverarc Capital Management
Massachusetts
$2.42K +$56.2K +5,535 +2%
MF
45
Magnetar Financial
Illinois
$632 -$27.9K -2,747 -4%
HM
46
HealthCor Management
New York
– -$613K -60,027 Closed
SCM
47
Suvretta Capital Management
New York
– -$361K -35,344 Closed
TRCT
48
Tower Research Capital (TRC)
New York
– +$173 +17 New
1
2

MLTX Hedge Fund Activity: Q2 2021 in Review

46 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2021, worth a combined $113M — up 3.5% from $109M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new MLTX positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was STALEY CAPITAL ADVISERS, adding an estimated $2.03M. The largest seller was Logos Global Management, cutting an estimated $1.52M.

  • 46 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2021, up from 42 in Q1 2021.
  • Funds reported $113M of MoonLake Immunotherapeutics stock for Q2 2021, up 3.5% quarter-over-quarter.
  • 6 funds opened new MoonLake Immunotherapeutics positions in Q2 2021 and 2 closed out, a net change of +4 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q2 2021 was STALEY CAPITAL ADVISERS, an estimated $2.03M added.
  • The largest MoonLake Immunotherapeutics seller in Q2 2021 was Logos Global Management, an estimated $1.52M sold.

Based on aggregated 13F filings for Q2 2021.